S. Swain

Oncology · New England Journal of Medicine · 2003–2022

A researcher in the Science corpus: 15 papers; trusts 5 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom S. Swain trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Baselga
  2. R. Nahta
  3. M. Scaltriti

Who trusts S. Swain overall

  1. Yuichiro Yoshioka
  2. M. Volkova

Papers from S. Swain's perspective

Ordered by how strongly the researchers S. Swain trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
  2. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
  3. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
  4. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. (Molecules and Cells)
  5. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. (Molecules and Cells)
  6. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. (Cell)
  7. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (Cancer Cell)
  8. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. (New England Journal of Medicine)
  9. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. (Molecules and Cells)
  10. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. (Cancer Research)

Their papers